Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the ...
Milestone Pharmaceuticals announced positive results from Ji Xing Pharmaceuticals' Phase 3 trial of etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT) in China, meeting primary and secondary endpoints with significant efficacy and safety. The trial aligns with Milestone's RAPID Phase 3 Study. Milestone and Ji Xing have a licensing agreement for etripamil in Greater China, with potential milestone payments and royalties.
Highlighted Terms
Related News
Ji Xing Pharmaceuticals reports positive Phase III trial data for etripamil nasal spray in treating PSVT, with significant efficacy and safety results.
Ji Xing Pharmaceuticals announced positive Phase III data for etripamil nasal spray in treating PSVT, showing significant efficacy and safety, with plans to advance regulatory approval in China.
Milestone Pharmaceuticals announced positive results from Ji Xing Pharmaceuticals' Phase 3 trial of etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT) in China, meeting primary and secondary endpoints with significant efficacy and safety. The trial aligns with Milestone's RAPID Phase 3 Study. Milestone and Ji Xing have a licensing agreement for etripamil in Greater China, with potential milestone payments and royalties.